Vestal Point Capital, LP Black Diamond Therapeutics, Inc. Transaction History
Vestal Point Capital, LP
- $1.32 Trillion
- Q3 2024
A detailed history of Vestal Point Capital, LP transactions in Black Diamond Therapeutics, Inc. stock. As of the latest transaction made, Vestal Point Capital, LP holds 5,028,500 shares of BDTX stock, worth $11 Million. This represents 1.66% of its overall portfolio holdings.
Number of Shares
5,028,500
Previous 2,100,000
139.45%
Holding current value
$11 Million
Previous $9.79 Billion
123.52%
% of portfolio
1.66%
Previous 0.73%
Shares
2 transactions
Others Institutions Holding BDTX
# of Institutions
117Shares Held
48.8MCall Options Held
1.84MPut Options Held
1.93M-
T. Rowe Price Investment Management, Inc. Baltimore, MD10.7MShares$23.5 Million0.03% of portfolio
-
Bellevue Group Ag Kuesnacht, V88.52MShares$18.7 Million0.62% of portfolio
-
Nea Management Company, LLC Timonium, MD4.45MShares$9.74 Million1.48% of portfolio
-
Black Rock Inc. New York, NY3.22MShares$7.05 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.32MShares$5.08 Million0.0% of portfolio
About Black Diamond Therapeutics, Inc.
- Ticker BDTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,339,500
- Market Cap $79.6M
- Description
- Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epide...